Beyond validating miR-222 overexpression in tamoxifen resistant cells, this is the first demonstration that upregulation of miR-222 increases PARP1 activation and PARPi sensitivity and decreases RAD51 foci formation in breast cancer cells. The gene discussed is PARP1; the disease is breast carcinoma.